Emerging evidence has shown reactive astrocytosis had been implicated as a potential driver or effect of AD pathological changes, and the elevated plasma GFAP levels were associated with amyloid pathology (Pereira et al., 2021; Teunissen et al., 2022). The gene discussed is GFAP; the disease is Alzheimer disease.